This highlights a further different effect of nanoceria in p53 proficient vs. deficient cells, whereas the oncogenic asset, normal in HaCaT though mutant in SCC or the prostate cancer cells, seems here less relevant. This evidence concerns the gene TP53 and prostate cancer.